Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene
Thursday, August 26, 2010 - 03:37
in Health & Medicine
Use of an experimental targeted drug to treat metastatic melanoma tumours with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in the August 26 New England Journal of Medicine...